Navigation Links
Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010
Date:8/3/2010

BEIJING, Aug. 3 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical") (NYSE: CCM), operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2010, before the U.S. market opens on August 18, 2010. Concord Medical's management will hold an earnings conference call at 8 AM on August 18, 2010 U.S. Eastern Time (8 PM on August 18, 2010 Beijing/Hong Kong time).

    Dial-in details for the earnings conference call are as follows:

    US:            +1.866.270.6057
    China:         +10-800-852-1490 China Netcom (South China)
                   +10-800-152-1490 China Telecom (North China)
                   +10-800-130-0399 China Telecom (South China)
    Hong Kong:     +800-96-3844
    International: +1.617.213.8891

    Passcode:      70681252

A replay of the conference call may be accessed by phone at the following number until August 25, 2010:

    US:            +1-888-286-8010
    International: +1-617-801-6888

    Passcode:      55593251

Additionally, a live and archived webcast of this conference call will be available at

SOURCE Concord Medical Services Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
2. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
3. Concord Grape Juice Has No Significant Impact on Body Weight
4. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
5. Concord Medical Announces New Centers Opening at Hospital Partner
6. Concord Medical Announces Share Repurchase Program
7. Concord Medical Files 2009 Annual Report on Form 20-F
8. Concord Medical Enters into Joint Venture Agreement with ChangAn Hospital
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:7/29/2014)... 2014 Summer is here, and that means it’s ... hike, swimming in a pool or laying out on the beach. ... ticks. The Puppy Store is here to help pet owners protect ... It’s almost impossible to completely keep fleas and ticks at bay, ... chances of their pets coming into contact with fleas and ticks. ...
(Date:7/29/2014)... 2014 A team of scientists, led ... PhD, has developed a blood test for Alzheimer’s disease ... development of Alzheimer’s disease interventions, according to an article ... puzzle, and this study represents one of several pieces ... past couple of years,” Ethell said. , The study, ...
(Date:7/29/2014)... cure most cases of cancer is to surgically remove ... is that the surgeon may fail to extract the ... a new technique, researchers at the University of Pennsylvania ... the entire tumor in the patient, increasing the likelihood ... injectable dye that accumulates in cancerous tissues much more ...
(Date:7/29/2014)... 29, 2014 As testosterone treatment lawsuits ... Bernstein Liebhard LLP notes that a new study is ... Type 2 diabetes. The research, which was published online ... June 30th, involved 88 men who suffered from Type ... aging male symptoms and erectile dysfunction. Roughly half of ...
(Date:7/29/2014)... Gerontological Society of America (GSA) and the National ... MD, PhD, of Columbia University as the 2014 recipient ... and Aging. , This award recognizes and honors the ... the field of creativity and aging shifted the conceptual ... and potential. Cohen inspired individuals to approach longevity asking ...
Breaking Medicine News(10 mins):Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Charon to receive 2014 Gene D. Cohen Award 2
... to hold sway on the degree of hangover one might ... has found. //Scottish researchers delved into this arena, and studied ... the clever lot benefit by being hangover less as compared ... ,The discomfort associated with a hangover, characterized by an unbearable ...
... Lilly Jaffe a six-year-old girl diagnosed with type 1 Diabetes ... of Chicago Medical Center on August 14. // Four days ... way to manufacturing insulin in her own body and ready ... started school., ,As she continued to do well, ...
... that severely ill malaria patients would benefit a lot ... Researchers from the Imperial College in London and experts ... replace fluids for children ill with malaria. ... the children who received the new treatment died, researchers ...
... report by Commonwealth Fund, employers are deducting health benefits ... cope with rising health care costs. // The higher ... to take individual insurance find it too expensive. Low-income ... may not have needed health care. ,An ...
... have great potentials in the fields of medicine and ... Dots (QDs) prove to be useful in advanced therapies ... ,A complete review of the latest literature and ... the nanotechnology website AzoNano. ,The review by Sandeep ...
... heart failure and men with treated prostate cancer are among ... Now, under new guidelines co-authored by a Hopkins cardiologist and ... Transplantation (ISHLT), they can and should be considered. ,“People ... have a chance to get a new heart,” says Stuart ...
Cached Medicine News:Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7Health News:Most people applying for coverage end up not buying it 2Health News:Most people applying for coverage end up not buying it 3Health News:Now, Even Older Adults and Some Cancer Patients can go for Heart Transplantation 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
Medicine Products: